January 7, 2016

AngioDynamics Reports Fiscal 2016 Second Quarter Results

  • Net sales of $89.2 million
  • GAAP loss of $0.01 per share; Non-GAAP adjusted EPS of $0.14
  • Operating cash generation of $9.6 million

ALBANY, N.Y., Jan. 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the second quarter of fiscal year 2016 ended November 30, 2015.

"In the second quarter, we managed the business effectively, despite lingering headwinds, and generated net sales of $89.2 million and adjusted EPS of $0.14, both of which were in the mid-range of our guidance," commented Joseph M. DeVivo, president and chief executive officer. "Our team has worked diligently to build a culture committed to quality and compliance and, in the quarter, our efforts were validated when the FDA removed the remaining warning letters against the Company. Additionally, we continue to execute our operational excellence plans and expect to complete the manufacturing transition from Queensbury to Glens Falls in January, which will further increase our operating leverage and improve cash flow generation. AngioDynamics now has a strong operational and regulatory foundation that we believe will contribute to top line growth, margin expansion and continued strong cash flow from operations.  

"From a products perspective, overall Peripheral Vascular business grew 3%, driven by a strong performance in Thrombus Management, which grew 17%. In addition, BioFlo continued to grow across all product segments in our Vascular Access business, including a strong sales quarter for our midline and dialysis products. BioFlo now represents 41% of our Vascular Access franchise. In Oncology/Surgery, our growth driver products, Microwave and NanoKnife, showed significant procedural and utilization growth offsetting slower capital sales. We believe procedural and utilization growth are a better indication of the opportunity for those two products.

"As we begin the second half of our fiscal year, we are moving past the Morpheus withdrawal and foreign currency headwinds that have impacted our recent top line performance. We are now fully focused on building on our improved operational foundation to continue our commercial momentum, especially with our growth driver products."

Second Quarter 2016 Financial Results

Net sales for the fiscal second quarter were $89.2 million, compared with $92.1 million a year ago. On a constant currency basis and excluding the impact of the Morpheus product discontinuance, sales were down 1% compared to the second quarter last year.

The following comparisons exclude the BSC supply agreement.  

Peripheral Vascular net sales in the second quarter were $51.1 million compared to $49.4 million in the fiscal year 2015 second quarter. Vascular Access net sales were $25.0 million compared to $28.0 million a year ago. Oncology/Surgery net sales were $12.4 million compared to $13.6 million in the prior year's second quarter. Overall, net sales in the U.S. were $70.7 million compared to $72.1 million in the 2015 fiscal year second quarter. International net sales were $17.8 million compared to $19.0 million a year ago, which included a 5% negative impact on revenues from foreign currency headwinds. 

The Company's GAAP net loss was $0.4 million, or $0.01 loss per share, compared to a net income of $1.3 million, or $0.04 per share, in the second quarter of fiscal 2015. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $5.1 million, or $0.14 per share, compared to adjusted net income of $6.2 million, or $0.17 per share, from the year ago second quarter. 

EBITDA was $8.4 million, or $0.23 per share, compared to $11.9 million, or $0.33 per share, a year ago. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $13.4 million, or $0.37 per share, compared to $15.9 million, or $0.44 per share, in the year ago comparable period. 

In the second quarter, the Company generated $9.6 million in operating cash flow. At November 30, 2015, cash and investments were $20.6 million and debt was $133.9 million.

Six Months Financial Results

For the six months ended November 30, 2015, net sales were $172.9 million compared to the $179.5 million reported a year ago. The Company's net loss was $1.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.05 per share, reported a year ago. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $9.0 million, or $0.25 per share, compared to net income of $11.9 million, or $0.33 per share, a year ago. EBITDA was $16.6 million, or $0.45 per share, compared to EBITDA of $21.8 million, or $0.61 per share, a year ago. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $25.3 million, or $0.69 per share, compared to $30.4 million, or $0.84 per share, in the year ago period.

Recent Events

  • The Company received letters from the United States Food and Drug Administration (FDA) closing out warning letters it received from the FDA in January 2011 regarding certain promotional activities related to the NanoKnife System, in May 2011 related to the company's Queensbury facility and in November 2014 related to the Glens Falls and Marlborough facilities. These actions resolved all outstanding FDA warning letters against AngioDynamics.
     
  • The company received eight regulatory clearances for products in various international markets, a total of 16 in the first half of the 2016 fiscal year.
     
  • The NanoKnife System was approved by South Korea's Ministry of Food and Drug Safety for the ablation of soft tissue. The Company is selling the NanoKnife system to healthcare providers in South Korea through exclusive distribution partnerships.  NanoKnife is now approved in 45 countries worldwide.
     
  • The Americas Hepato-Pancreato-Billiary Association (AHPBA) registered its first patient into a registry to capture patient and effectiveness data on the use of Irreversible Electroporation (IRE) utilizing NanoKnife for patients with pancreatic cancer.

Fiscal Year 2016 and Third Quarter Financial Guidance

The Company revised its FY2016 net sales guidance to $353 to $359 million and adjusted earnings per share (EPS) of $0.59 to $0.63. The Company expects third quarter net sales to be in the range of $84 to $87 million and adjusted EPS of $0.10 to $0.14.

Conference Call

AngioDynamics will host a conference call today at 4:30 p.m. ET to discuss its second quarter results. To participate in the live call by telephone, please call 1-888-455-2263 and reference the Conference ID: 1443554. In addition, a live webcast and archived replay of the call will be available at investors.angiodynamics.com. To access the live webcast, please go to the website 15-minutes prior its start to register, download and install the necessary software.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported net sales excluding a supply agreement; adjusted sales growth; EBITDA (income before interest, taxes, depreciation and amortization); adjusted EBITDA; adjusted gross profit; adjusted net income and adjusted earnings per share. Additionally, this press release evaluates results on a constant currency basis. As a non-GAAP measure, constant currency excludes the impact of foreign currency exchange rate fluctuations. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo, BioFlo, Morpheus, NanoKnife and AngioVac, are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly report on Form 10-Q for the fiscal period ended August 31, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.


  
ANGIODYNAMICS, INC. AND SUBSIDIARIES 
CONSOLIDATED INCOME STATEMENTS 
(in thousands, except per share data) 
         
         
 Three months ended Six months ended 
 Nov 30,  Nov 30, Nov 30, Nov 30, 
  2015    2014   2015   2014  
 (unaudited) (unaudited) 
          
Net sales$  89,234   $  92,149  $  172,937  $  179,480  
Cost of sales   43,400     44,493     83,929     85,999  
Gross profit   45,834     47,656     89,008     93,481  
% of net sales 51.4%  51.7%  51.5%  52.1% 
         
Operating expenses        
Research and development    6,179     6,069     12,381     12,787  
Sales and marketing   20,569     20,983     41,128     41,050  
General and administrative   8,089     7,973     15,516     15,296  
Medical device excise tax   978     1,076     1,981     2,071  
Amortization of intangibles   4,483     4,061     8,898     8,076  
Change in fair value of contingent consideration   306     617     661     1,418  
Acquisition, restructuring and other items, net   3,913     2,302     6,056     4,966  
Total operating expenses   44,517     43,081     86,621     85,664  
Operating  income (loss)   1,317      4,575     2,387     7,817  
Other income (expense), net   (2,045)    (1,746)    (3,789)    (3,570) 
Income (loss) before income taxes   (728)    2,829     (1,402)    4,247  
Income tax expense (benefit)   (366)    1,491     (283)    2,439  
Net income (loss)$  (362) $  1,338  $  (1,119) $  1,808  
         
Earnings (loss) per share        
Basic$  (0.01) $  0.04  $  (0.03) $  0.05  
Diluted$  (0.01) $  0.04  $  (0.03) $  0.05  
         
Weighted average shares outstanding        
Basic   36,140     35,595     36,051     35,475  
Diluted   36,140     36,127     36,051     36,012  
         

 

 
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
         
         
         
Reconciliation of Gross Profit to non-GAAP Adjusted Gross Profit
 
         
 Three months ended Six months ended 
 Nov 30 , Nov 30, Nov 30, Nov 30, 
  2015   2014   2015   2014  
 (unaudited) (unaudited) 
         
Gross profit$  45,834  $  47,656  $  89,008  $  93,481  
         
Recall expenses included in cost of sales   (71)    -      (98)    -   
Adjusted gross profit$  45,763  $  47,656  $  88,910  $  93,481   
Adjusted gross profit % of sales 51.3%  51.7%  51.4%  52.1% 
          
Reconciliation of Net Income to non-GAAP Adjusted Net Income:
 
         
 Three months ended Six months ended 
 Nov 30, Nov 30, Nov 30 , Nov 30, 
  2015   2014   2015   2014  
 (unaudited) (unaudited) 
         
Net income (loss)$  (362) $  1,338  $  (1,119) $  1,808  
         
Recall expenses included in cost of sales   (71)    -      (98)    -   
Amortization of intangibles   4,483     4,061     8,898     8,076  
Change in fair value of contingent consideration   306     617      661     1,418  
Acquisition, restructuring and other items, net (1)   3,913     2,302     6,056     4,966  
Tax effect of non-GAAP items (2)   (3,211)     (2,089)    (5,364)    (4,389) 
Adjusted net income$  5,058  $  6,229  $  9,034  $  11,879  
         
         
Reconciliation of Diluted Earnings Per Share to non-GAAP Adjusted Diluted Earnings Per Share:
 
         
 Three months ended Six months ended 
  Nov 30, Nov 30, Nov 30, Nov 30, 
  2015   2014   2015   2014  
 (unaudited) (unaudited) 
         
Diluted earnings (loss) per share$  (0.01) $  0.04  $  (0.03) $  0.05  
         
Recall expenses included in cost of sales   (0.00)    -      (0.00)    -   
Amortization of intangibles   0.12     0.11     0.24     0.22  
Change in fair value of contingent consideration   0.01     0.02     0.02     0.04  
Acquisition, restructuring and other items, net (1)   0.11     0.06     0.17     0.14  
Tax effect of non-GAAP items (2)   (0.09)    (0.06)    (0.15)    (0.12) 
Adjusted diluted earnings per share$  0.14  $  0.17  $  0.25  $  0.33  
         
         
Adjusted diluted sharecount   36,416     36,127     36,545     36,012  
         
(1)  Includes costs related to mergers and acquisition activities, integrations, restructurings, debt refinancings, litigation, and other items. 
(2)  Represents the net tax effect of non-GAAP adjustments.  
 

 

 
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
           
           
           
Reconciliation of Net Income to EBITDA and Adjusted EBITDA:       
           
   Three months ended Six months ended 
   Nov 30, Nov 30, Nov 30, Nov 30, 
     2015   2014   2015   2014  
   (unaudited) (unaudited) 
           
Net income (loss)$  (362) $  1,338  $  (1,119) $  1,808  
           
Income tax expense (benefit)   (366)    1,491     (283)    2,439  
Other income (expense), net   2,045     1,746     3,789     3,570  
Depreciation and amortization   7,078     7,299     14,182     13,999  
EBITDA   8,395     11,874     16,569     21,816  
           
Recall expenses included in cost of sales   (71)    -      (98)     -   
Change in fair value of contingent consideration   306     617     661     1,418  
Acquisition, restructuring and other items, net (1,2)   3,536     1,927     5,302     4,216  
Stock-based compensation   1,234     1,506     2,860     2,901  
Adjusted EBITDA$  13,400  $  15,924  $  25,294  $  30,351  
           
Per diluted share:        
EBITDA $  0.23  $  0.33  $  0.45  $  0.61  
Adjusted EBITDA$   0.37  $  0.44  $  0.69  $  0.84  
           
           
(1)  Includes costs related to mergers and acquisition activities, integrations, restructurings, debt refinancings, litigation, and other items. 
(2)  Excludes depreciation expense captured in the depreciation and amortization component of the reconciliation.  
  

 

  
ANGIODYNAMICS, INC. AND SUBSIDIARIES 
PRELIMINARY NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY 
(unaudited in thousands) 
                     
                     
 Three months ended Six months ended 
       Currency Constant       Currency Constant 
 Nov 30, Nov 30, % Impact Currency Nov 30, Nov 30, % Impact Currency 
  2015   2014  Growth (Pos) Neg Growth  2015   2014  Growth (Pos) Neg Growth 
                      
Net Sales by Product Category                     
Peripheral Vascular$  51,051  $  49,440   3%     $  98,158   $  96,801   1%     
Vascular Access   25,023     27,968   -11%        49,667     54,393   -9%     
Oncology/Surgery   12,422     13,634   -9%        23,706     25,996   -9%     
   Total Excluding Supply Agreement     88,496     91,042   -3%  1%  -2%    171,531     177,190   -3%  1%  -2% 
Supply Agreement   738     1,107   -33%  0%  -33%    1,406     2,290   -39%  0%  -39% 
   Total$  89,234  $  92,149   -3%  1%   -2% $  172,937  $  179,480   -4%  1%  -3% 
                      
Net Sales by Geography                     
United States$  70,651  $  72,058   -2%  0%  -2% $  139,021  $  140,438   -1%  0%  -1% 
International   17,845     18,984   -6%  5%  -1%    32,510     36,752   -12%  6%  -6% 
Supply Agreement   738      1,107   -33%  0%  -33%    1,406     2,290   -39%  0%  -39% 
   Total$  89,234  $  92,149   -3%  1%  -2% $  172,937  $  179,480   -4%  1%  -3% 
                     

 

  
ANGIODYNAMICS, INC. AND SUBSIDIARIES 
CONSOLIDATED BALANCE SHEETS 
(in thousands) 
      
      
  Nov 30, May 31 
   2015   2015  
  (unaudited) (unaudited) 
Assets    
Current Assets    
 Cash and cash equivalents$  18,996  $  18,391  
 Marketable securities   1,639     1,689  
   Total cash and investments   20,635     20,080  
      
 Accounts receivable, net   53,118     58,428  
 Inventories   70,813     67,388  
 Prepaid income taxes   1,123     770  
 Prepaid expenses and other   5,869     4,783  
   Total current assets   151,558     151,449  
      
Property, plant and equipment, net   51,153     54,560  
Intangible assets, net   172,511     181,806  
Goodwill   361,252     361,252  
Deferred income taxes, long-term   19,826     19,268  
Other non-current assets   4,071     5,288  
   Total Assets$  760,371  $  773,623  
      
Liabilities and Stockholders' Equity    
Accounts payable$  21,701  $  23,668  
Accrued liabilities    16,975     18,331  
Income taxes payable   403     439  
Current portion of long-term debt   11,250     8,750  
Current portion of contingent consideration   9,775     9,969  
   Total current liabilities   60,104     61,157  
Long-term debt, net of current portion   122,660     128,910  
Deferred income taxes, long-term   1,119     1,119  
Contingent consideration, net of current portion   28,074     37,415  
Other long-term liabilities   775     -  
   Total Liabilities   212,732     228,601  
      
Stockholders' equity   547,639     545,022  
   Total Liabilities and Stockholders' Equity  $  760,371  $  773,623  
      

 

  
ANGIODYNAMICS, INC. AND SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF CASH FLOWS 
(in thousands) 
         
         
 Three months ended Six months ended 
 Nov 30, Nov 30, Nov 30, Nov 30, 
  2015   2014   2015   2014  
 (unaudited) (unaudited) (unaudited) (unaudited) 
         
Cash flows from operating activities:        
Net  income  (loss) $  (362) $  1,338  $  (1,119) $  1,808  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:           
Depreciation and amortization   7,197     7,299     14,420     13,999  
Stock-based compensation   1,234     1,506     2,860     2,901  
Change in fair value of contingent consideration   306     617     661     1,418   
Fixed and intangible asset impairments and disposals   402     -      622     -   
Deferred income taxes   (412)    1,575     (607)    3,685  
Change in accounts receivable allowance   229     218     338     345  
Other   (248)    (279)    (261)    (89) 
Changes in operating assets and liabilities, net of acquisitions:         
Receivables   (1,017)    (2,746)    4,908     3,069  
Inventories   3,449     (4,894)    (3,473)    (14,081) 
Prepaid and other assets   354      (876)    (1,600)    (3,712) 
Accounts payable and accrued liabilities   (1,553)    (5,905)    (2,471)    (6,138) 
   Net cash provided by (used in) operating activities    9,579      (2,147)    14,278     3,205  
         
Cash flows from investing activities:         
Additions to property, plant and equipment    (425)    (2,419)    (1,168)    (7,523) 
Acquisition of intangible assets    -      (96)    -       (250) 
Other cash flows from investing activities    25     -      25     -   
Net cash provided by (used in) investing activities    (400)    (2,515)    (1,143)    (7,773) 
         
Cash flows from financing activities:        
Repayment of long-term debt    (2,500)    (1,250)    (3,750)    (2,500) 
Proceeds from issuance  of long-term debt and revolver borrowings    -      15,000     -      15,000  
Payment of Contingent Consideration    (7,750)    (9,122)    (9,850)    (11,222) 
Proceeds from exercise of stock options and ESPP    (49)    1,144     1,230     2,103  
Net cash provided by (used in) financing activities    (10,299)    5,772     (12,370)    3,381  
         
Effect of exchange rate changes on cash    (152)    (41)    (160)    (41) 
Increase  (Decrease) in cash and cash equivalents    (1,272)    1,069     605     (1,228) 
         
Cash and cash equivalents        
Beginning of period    20,268      13,808     18,391     16,105   
End of period $  18,996  $  14,877  $  18,996  $  14,877  
         


Company Contact:

AngioDynamics Inc.

Caitlin Stefanik

(518) 795-1418

cstefanik@angiodynamics.com



Investor Relations Contacts:

EVC Group, Inc.

Doug Sherk; Chris Dailey

(646) 445-4801

dsherk@evcgroup.com.; cdailey@evcgroup.com



Media Contact:

EVC Group, Inc.

Dave Schemelia

(646) 201-5431

dave@evcgroup.com

Primary Logo

Source: AngioDynamics

News Provided by Acquire Media


Close window | Back to top


Copyright 2017 AngioDynamics